New transplant method aims to reduce dangerous side effects in blood cancer patients
NCT ID NCT05617625
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This phase II trial tests a special stem cell transplant that removes immune T-cells from the donor's blood to lower the risk of graft-versus-host disease (GVHD), a serious complication where the donor cells attack the patient's body. About 50 adults with myelodysplastic syndrome (a blood cancer) will receive chemotherapy followed by the processed transplant. The study is currently suspended, and its main goal is to see if this method reduces GVHD severity and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Miami Cancer Institute
Miami, Florida, 33176, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD34+ enriched, T-cell depleted stem cell transplant using the CliniMACS system
What this could lead to
If successful, this approach could reduce the severity of graft-versus-host disease after stem cell transplants, improving outcomes for patients with myelodysplastic syndrome.
What could go wrong
This is a small, early-phase trial that is currently suspended. The procedure carries risks including infection, organ damage, and transplant failure, and it may not work for all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.